Clinical Trials · NCT01652729
Comparison Study of the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly Suspension to Sitagliptin and Placebo in Subjects With Type 2 Diabetes Mellitus
- Phase
- Phase 3
- Recruitment status
- Completed
- Sponsor
- AstraZeneca
- Enrollment
- 365
- Start date
- Feb 2013
- Locations
- 60 sites, United States
- Primary endpoint
- Change in HbA1c (Glycosylated Hemoglobin) From Baseline to Week 28